Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. - Wikidata - wikimedia - TriplyDB

Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia.

Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia.

http://www.wikidata.org/entity/Q34293391

about

Aurora Kinase Inhibitors: Current Status and Outlook Recent advances in the development of Aurora kinases inhibitors in hematological malignancies Inhibition of Aurora kinase B is important for biologic activity of the dual inhibitors of BCR-ABL and Aurora kinases R763/AS703569 and PHA-739358 in BCR-ABL transformed cells A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumors.Aurora kinases: novel therapy targets in cancers A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis.The aurora kinases in cell cycle and leukemia The chromosomal passenger complex (CPC) as a key orchestrator of orderly mitotic exit and cytokinesis.New strategies in acute myelogenous leukemia: leukemogenesis and personalized medicine.Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma.Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia.A framework for identification of actionable cancer genome dependencies in small cell lung cancer.Discovery of benzo[e]pyridoindolones as kinase inhibitors that disrupt mitosis exit while erasing AMPK-Thr172 phosphorylation on the spindle.Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumors.Aurora kinase inhibitors: progress towards the clinic ENMD-2076 for hematological malignancies.Novel therapies for children with acute myeloid leukaemia.Mitosis as an anti-cancer drug target.Novel drugs for older patients with acute myeloid leukemia.PRMT1 promotes mitosis of cancer cells through arginine methylation of INCENP.Novel approaches to pediatric leukemia treatment.Are Accurins the cure for Aurora kinase inhibitors?A phase 1 study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients with acute myeloid leukemia.The Aurora kinase inhibitors in cancer research and therapy.Significance of AZD1152 as a potential treatment against Aurora B overexpression in acute promyelocytic leukemia.Emerging cell cycle inhibitors for acute myeloid leukemia.Clinical Development of Anti-mitotic Drugs in Cancer.Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors.Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target.Preclinical evaluation of the Aurora kinase inhibitors AMG 900, AZD1152-HQPA, and MK-5108 on SW-872 and 93T449 human liposarcoma cells.Polo-like kinases in AML.[(14) C]-AZD1152 drug substance manufacture: challenges of an IV-infusion dosed human mass balance study in patients.A phase II trial of AZD1152 in relapsed/refractory diffuse large B-cell lymphoma.MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia.Therapeutic polymeric nanoparticles and the methods of making and using thereof: a patent evaluation of WO2015036792.

P2860

Q26770583-8607D306-004B-473E-9416-9334999D17EC Q26775723-F2F64D8D-C2F3-4829-A7F1-5D580FDAAB46 Q28545195-DC4809FB-4331-42F2-B5C7-E2F9378A87A9 Q33406722-3A7B0877-798E-4B0F-9F06-3891AFB9D281 Q33618929-4636F4D6-D87C-426E-828E-D19791AA410D Q33897070-85A474B7-0B30-4C10-BD97-0E12C9690234 Q34203062-BA09A813-B972-4C7F-8763-4762364EB252 Q34668857-A62877B9-AFE6-4409-8E66-69C71503370E Q34715598-D35CFE97-7A74-4A8A-9868-D27A4DE716FD Q34817365-693D44F1-B652-428C-9C79-08BB5F0C1177 Q35356178-255318A7-3353-4024-899A-AB49ECD7CEB3 Q35550246-315C0B78-9BF0-4911-8364-A36A23ED88B1 Q35819646-BE1C0A38-9720-4FE3-B96F-3ED34FCCBE7E Q36192072-C0FB5ACA-FC13-4D99-87B3-7121D61083B9 Q36342432-3B049A9E-A866-483B-B811-DE8D60D251E7 Q36355904-AA0D0E6C-11BD-4891-85F7-1DE43A25C25A Q36469916-ADE6C810-D22C-4650-8E15-6681EC100EB2 Q37179371-2282BBE2-8F29-4E5E-B63A-B2548DA1AFF5 Q37366202-D7687BCC-41A0-4541-ACD3-95F3D8FBC3E7 Q37986455-40044EA7-4FFE-4265-AB75-F40AF7990E7A Q37991379-190F8F00-2E6B-4B4F-9417-6D4534FA21AA Q38096798-4118FD5B-AFA8-4787-A2B8-AE0EF8A4C8CF Q38115166-F88E918D-967E-4533-9D53-44DAD0F9AC76 Q38241761-42BDC30C-8838-4CDB-8F8B-01926BD82CEB Q38262590-2CBBC171-C6A4-43C8-B546-54B95EFDE453 Q38500371-53FEB8C7-6233-4622-BB65-18C92278AA3B Q38729117-15A218F9-AD57-4FAC-B59F-F564361AE4E5 Q38735991-1438D841-69A6-4D62-B694-629191760AE6 Q38756932-D57C1C19-DAA3-42FE-8D45-7DE6EEFEB316 Q38777275-0C7891FD-560D-4E61-9A11-8A0E574CC3F2 Q38785380-84E78721-BC19-47A3-9379-E7F0BC4AE36A Q39363642-4B6CA862-8CA6-46E2-BC89-6BA3FD43DB9D Q39608458-596C0D28-618D-4BB2-B996-5CFF9AD1DC30 Q41368368-B781155C-BE65-47F4-B376-3E6A2C46C479 Q47339376-C309C895-F1AA-4D86-BF02-D620CC031D7B Q50939437-ED0A3368-EFE9-43D4-93C4-FE1F9342B143 Q53159205-2C0C7662-A2C5-4856-982F-DCCD8A27FCC4 Q54287946-84AA0FE8-0658-4835-B96E-62DDFF855D31 Q54498929-F794C94A-4EAA-4541-A5C2-5E00A35CBCDF Q55022875-FEA81567-DEC5-492F-9013-75B8AACC45DB

P2860

Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia.

http://www.wikidata.org/entity/Q34293391

description

2011 nî lūn-bûn

@nan

2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Phase 1/2 study to assess the ...... vanced acute myeloid leukemia.

@ast

Phase 1/2 study to assess the ...... vanced acute myeloid leukemia.

@en

Phase 1/2 study to assess the ...... vanced acute myeloid leukemia.

@nl

type

label

Phase 1/2 study to assess the ...... vanced acute myeloid leukemia.

@ast

Phase 1/2 study to assess the ...... vanced acute myeloid leukemia.

@en

Phase 1/2 study to assess the ...... vanced acute myeloid leukemia.

@nl

prefLabel

Phase 1/2 study to assess the ...... vanced acute myeloid leukemia.

@ast

Phase 1/2 study to assess the ...... vanced acute myeloid leukemia.

@en

Phase 1/2 study to assess the ...... vanced acute myeloid leukemia.

@nl

P1433

Q34293391-43195101-6B11-410E-BBC7-03CAABD33274

P1476

Q34293391-E6A7AE2F-4EA3-4496-8178-243B9B828DB4

P2093

Q34293391-0851F7A3-0346-419F-865C-D1E9C2122D65

Q34293391-71B4B420-F3E5-40ED-92B8-9DCF72782FC6

Q34293391-78150398-4239-41A1-B14B-92FA96FEE7BA

Q34293391-8B3D099A-57F4-4D0F-B7FF-6952C4D17351

Q34293391-8B45C3CD-7ACB-493B-8F6D-48BA4C34068C

Q34293391-94FAA654-B211-4345-B0EA-7FCDF47DA4CA

Q34293391-BDA8F01D-8635-400D-ACF1-6D7711876401

Q34293391-E23D6C5E-1F70-4597-B25A-699429A56527

P2860

Q34293391-0388ECF6-7F79-4283-A5FF-F71C2D9EAFF8

Q34293391-06B5D37F-4171-428E-82BC-D68F48BDE3A7

Q34293391-07471FB1-8369-4535-A3A5-23F0D14301DF

Q34293391-11E41ADE-24FC-403B-97F7-CCDEEC07774E

Q34293391-2720A4BF-A532-4A88-A43C-A438FD25C89D

Q34293391-2A013488-6A44-4639-9840-B20C42B377DF

Q34293391-2B059448-2467-4A9B-B4C3-7AA2563640D9

Q34293391-410B802C-0785-4B4B-937D-6001B62DAE4D

Q34293391-4392DFE0-3B66-4EDB-855E-D4E7EA9FEA71

Q34293391-4F7C3796-5AC4-4946-A03C-BB508E37CE6D

P304

Q34293391-CCA18157-0A14-4080-AFB9-7C0A2FF671F3

P31

Q34293391-31F13345-2311-4676-8E62-4118FFF85230

P356

Q34293391-B992AB58-F20E-49A3-B5D9-E1985C3FA847

P407

Q34293391-D099B6DA-987D-445A-A9DF-55D05608DAAE

P433

Q34293391-1BB36C88-C0B3-428C-8125-129D8E7974C1

P478

Q34293391-644F0C6C-83DC-4A79-A035-4C812E1B3E67

P50

Q34293391-0B019FCB-4303-4B3A-BE35-BFB738705DF2

Q34293391-30BF2663-1562-41FB-8CDB-096509F52A23

Q34293391-4912A989-7AC4-473D-9BC6-DB66BCDC7847

Q34293391-6BE0F078-E9F4-4865-8E27-91DAC94913DE

Q34293391-6FAF7178-3901-49C4-B159-F2F39E2E93BF

Q34293391-71A51166-4316-4CCD-9223-089A512DEE4D

Q34293391-816E20BC-3F0F-4085-A0E6-CDCB2AECE6C5

Q34293391-B51F5AE2-4ABF-4552-89C4-A60B717FEE34

Q34293391-D053AE66-0BBB-4C15-BA10-A866AE585423

P577

Q34293391-81D639F6-D943-4AC0-9421-8FEEE503D2D2

P5875

Q34293391-4C628CB4-1C1A-4C77-87BD-6B14BADF1045

P698

Q34293391-6072B358-2247-4B5F-845B-C1D41E23C6B5

P921

Q34293391-329B85C3-CD21-4E47-BCF0-0314C9594734

Q34293391-A0A9C441-BDB4-4933-BA87-90936658F08F

P932

Q34293391-60019161-8FC0-401C-BC88-C78E94F6F5C5

P356

BLOOD-2011-07-366930

P1433

P1476

Phase 1/2 study to assess the ...... vanced acute myeloid leukemia.

@en

P2093

Alison Goudie

http://www.w3.org/2001/XMLSchema#string

Ellin Berman

http://www.w3.org/2001/XMLSchema#string

Gert Ossenkoppele

http://www.w3.org/2001/XMLSchema#string

Jean-Yves Cahn

http://www.w3.org/2001/XMLSchema#string

Mojca Jongen-Lavrencic

http://www.w3.org/2001/XMLSchema#string

Paul Stockman

http://www.w3.org/2001/XMLSchema#string

Philippe Rousselot

http://www.w3.org/2001/XMLSchema#string

Sophie Rigaudeau

http://www.w3.org/2001/XMLSchema#string

P2860

Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity

Two-sided confidence intervals for the single proportion: comparison of seven methods

A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors.

Acute myeloid leukemia.

Independent prognostic factors for AML outcome.

Acute myeloid leukemia and acute promyelocytic leukemia.

Aurora kinases link chromosome segregation and cell division to cancer susceptibility.

Aurora kinases: shining lights on the therapeutic horizon?

Acute myeloid leukemia and myelodysplastic syndromes in older patients.

Modeling the temporal evolution of the spindle assembly checkpoint and role of Aurora B kinase

P304

6030-6036

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2011-07-366930

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P50

Hagop Kantarjian

Giovanni Martinelli

Pieter Sonneveld

P577

2011-10-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51696728

http://www.w3.org/2001/XMLSchema#string

P698

21976672

http://www.w3.org/2001/XMLSchema#string

P921

P932

4186639

http://www.w3.org/2001/XMLSchema#string